New dual-targeting CAR t therapy tested for hard-to-treat lymphoma
NCT ID NCT05169489
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested a new treatment called bbT369 for people with a type of blood cancer (B cell non-Hodgkin's lymphoma) that had come back or stopped responding to other treatments. The therapy uses a patient's own immune cells, which are modified to better recognize and attack cancer cells. The study aimed to check safety and how well the treatment works, but it was ended early.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE-LARGE B-CELL LYMPHOMA (DLBCL) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Colorado Blood Cancer Institute
Denver, Colorado, 80218, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
Sarah Cannon
Nashville, Tennessee, 37203, United States
-
Stanford Cancer Institute
Stanford, California, 94305, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Can a Two-Drug combo keep aggressive lymphoma at bay?
- Can donor immune cells be engineered to fight blood cancer?
- Can a simple blood test spot lymphoma earlier?
- Can a 'Universal' cancer target outsmart resistant blood cancers?
- What happens years after CAR-T therapy? a study aims to find out